Item 8.01 Other Events.
On
Both studies are designed to explore the potential of Proteostasis' proprietary cystic fibrosis transmembrane conductance regulator (CFTR) modulator combinations that include dirocaftor, posenacaftor and nesolicaftor, a CFTR potentiator, corrector and amplifier, respectively. The MHRA's scientific advice outlined a clear path forward toward the initiation and execution of the proposed two-pronged Phase 3 program, including establishment of a common safety database to support the safety profile of the proprietary combination, all toward the goal of supporting a Marketing Authorization Application for dirocaftor, posenacaftor and nesolicaftor. Both trials are expected to begin in 2020 and can run concurrently, building on the safety and efficacy database Proteostasis has established to date in over 300 patients with CF. The Company will continue to seek additional advice from other major regulatory agencies throughout 2020.
The CHOICES trial (Crossover trial based on Human Organoid Individual response in CF - Efficacy Study) is designed to be the first ever personalized medicine-based study in CF. CHOICES seeks to translate promising responses from an ex vivo organoids study of PTI modulators in rare CF mutations that is part of a pan-European strategic initiative, known as HIT-CF (Human Individualized Therapy of CF), whose goal is to accelerate the development of, and access to, personalized therapies for CF patients. The MORE trial (Modulator Options to RestorE CFTR study) is designed as a global, Phase 3, randomized, placebo-controlled study in CF subjects with the common F508del homozygous mutation, and will seek to confirm the positive efficacy and tolerability results from a recently completed Phase 2 study of the Proteostasis CFTR modulator triple combination.
Safe Harbor
To the extent that statements in this release are not historical facts, they are
forward-looking statements reflecting the current beliefs and expectations of
management made pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Words such as "aim," "may," "will," "expect,"
"anticipate," "estimate," "intend," and similar expressions (as well as other
words or expressions referencing future events, conditions or circumstances) are
intended to identify forward-looking statements. Examples of forward-looking
statements made in this release include, without limitation, statements
regarding the potential of our proprietary combination therapies for the
treatment of CF, the potential benefit to patients of our proprietary
combination therapies, expected timing of patient enrollment in our clinical
studies and cohorts for our clinical programs, including our planned Phase 3
programs and initiation of registrational or pivotal studies. Forward-looking
statements made in this release involve substantial risks and uncertainties that
could cause actual results to differ materially from those expressed or implied
by the forward-looking statements, and we, therefore cannot assure you that our
plans, intentions, expectations or strategies will be attained or achieved. Such
risks and uncertainties include, without limitation, the possibility final or
future results from our drug candidate trials (including, without limitation,
longer duration studies) do not achieve positive results or are materially and
negatively different from or not indicative of the preliminary results reported
by the Company (noting that these results are based on a small number of
patients and small data set), uncertainties inherent in the execution and
completion of clinical trials (including, without limitation, the possibility
that FDA or other regulatory agency comments delay, change or do not permit
trial commencement, or intended label, or the FDA or other regulatory agency
requires us to run cohorts sequentially or conduct additional cohorts or
pre-clinical or clinical studies), in the enrollment of CF patients in our
clinical trials in a competitive clinical environment, in the timing of
availability of trial data, in the results of the clinical trials, in possible
adverse events from our trials, in the actions of regulatory agencies, in the
endorsement, if any, by therapeutic development arms of CF patient advocacy
groups (and the maintenance thereof), and those set forth in our Annual Report
on Form 10-K for the year ended
The above information is not an admission as to the materiality of any
information therein. The Company undertakes no duty or obligation to update or
revise the information contained in this report, although it may do so from time
to time as its management believes is appropriate. Any such updating may be made
through the filing of other reports or documents with the
--------------------------------------------------------------------------------
© Edgar Online, source